You are here

What is the role of the mineralocorticoid receptor in diabetic cardiac myopathy?

Patients with diabetes are disproportionally affected by the incidence of cardiovascular disease (CVD); diabetic cardiac myopathy (DCM) affects ~20-25% of patients with diabetes. New therapies are needed to address this significant unmet need in the diabetic population. Mineralocorticoid receptor (MR) antagonists (MRA) are protective in DCM but side effects caused by poor kidney function limit its use in the clinic. This project will test a new MRA in development with an improved safety profile in a model of DCM. Diabetic mice (STZ model) will be given vehicle, a standard MRA or a novel MRA and the impact on cardiac remodelling, cardiac and renal function and diabetic metabolic endpoints will be investigated to determine any benefit of the new MRA for DCM. Techniques will include animal models, immunohistochemistry, cell culture RNA and protein isolation, RT PCR and western blot techniques. If time permits, bioinformatic analysis of data bases of patients with cardiac disease.
Essential criteria: 
Minimum entry requirements can be found here:
heart disease mineralocorticoid receptor macrophage cardiac fibrosis
Available options 
Masters by research
Masters by coursework
Time commitment 
Top-up scholarship funding available 
Physical location 
Baker Heart and Diabetes Institute, Commercial Rd, Prahran.
Assoc Prof 
Judy de Haan

Want to apply for this project? Submit an Expression of Interest by clicking on Contact the researcher.